Cutia Therapeutics (HKG:2487) said a post-hoc analysis of its Phase 3 clinical trial for CU-10201, a topical 4% minocycline foam for moderate to severe facial acne vulgaris, has been accepted for oral presentation at the 20th China Dermatologist Association Annual Meeting, according to a Monday bourse filing.
The analysis found early efficacy, with significant improvement in inflammatory lesions within the first week of treatment, and further gains in the second week, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.